Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Prime Medicine

Prime Medicine IPO

$1.23B
Series B Valuation, Jul 2021
Register for details
For more details on financing and valuation of private companies similar to Prime Medicine before its IPO, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Prime Medicine IPO date and status

2019
Founded
Oct 2022
IPO Completed

Company details

Prime Medicine is a gene-editing biotechnology company. Prime Medicine was founded in 2019 by Andrew Anzalone and is headquartered in Cambridge, MA.
Founded
2019
Headquarters
Cambridge, MA, United States
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
$1.23B
Total Funding
$315.76MM
Last Funding Round
Series B

Learn more about Prime Medicine

To invest in Prime Medicine pre-IPO

Can you invest in Prime Medicine pre-IPO?

You may invest in Prime Medicine as it is a public company listed on the NASDAQ with ticker PRME. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Prime Medicine before it goes public?

You can no longer sell shares of Prime Medicine on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Prime Medicine shares?

Forge can no longer determine the value of Prime Medicine shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Prime Medicine a publicly traded company?

Prime Medicine became a public company following its IPO on 10/10/2022 and is now traded on the NASDAQ under the ticker PRME.

To learn more about Prime Medicine potential IPO

Will Prime Medicine go IPO?

Prime Medicine became a public company following its IPO on 10/10/2022 and is now traded on the NASDAQ under the ticker PRME.

What is Prime Medicine’s IPO price?

The IPO price of Prime Medicine is not currently available.

When was Prime Medicine founded?

Prime Medicine was founded in 2019.

What is Prime Medicine funding to date?

Prime Medicine has raised $315.76MM to date.

Prime Medicine pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
07/13/2021 Series B $200MM $4.38 $1.23B Arch Venture Partners, Casdin Capital, Cormorant Asset Management, F-Prime Capital, Gv, Moore Strategic Ventures, Newpath Partners, Public Sector Pension Investment Board, Redmile Group, Samsara Biocapital, T. Rowe Price
Price per Share
$ xx.xx
Shares Outstanding
45,658,957
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Casdin Capital, Cormorant Asset Management, F-Prime Capital, Gv, Moore Strategic Ventures, Newpath Partners, Public Sector Pension Investment Board, Redmile Group, Samsara Biocapital, T. Rowe Price
10/15/2020 Series A $115.76MM $1.00 $231.52MM Arch Venture Partners, F-Prime Capital, Gv, Newpath Partners
Price per Share
$ xx.xx
Shares Outstanding
115,761,842
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Arch Venture Partners, F-Prime Capital, Gv, Newpath Partners

Prime Medicine IPO news and media highlights

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?

Prime Medicine, Inc.’s PRME shares have risen 16.4% in the past three months compared with the industry’s growth of 10.9%. The stock has also outperformed the sector and the S&P 500. The encouraging pipeline progress of this biotechnology company, focused on developing the next generation of gene editing therapies, is a positive. Innovation is imperative in the dynamic biotech sector and companies with a differentiated pipeline catch the eye of investors.

Prime Medicine prices IPO for CRISPR 3.0

Prime Medicine, a Cambridge, Mass.-based gene editing company founded by Harvard biochemist David Liu, has raised $175 million in its IPO and will begin trading Thursday on the Nasdaq. The biotech world views this as CRISPR 3.0, from the same man who invented CRISPR 2.0. It's also one of the most successful U.S. IPOs in recent memory, as Prime sold 1.4 million shares more than expected while hitting the middle of its $17-$19 price range for a $1.7 billion fully diluted market value.

Prime Medicine Announces Pricing of Upsized Initial Public Offering

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being offered by Prime Medicine. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,544,117 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.

Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing

Prime Medicine™, a company delivering on the promise of Prime Editing to provide lifelong cures to patients, today announced its launch with $315 million in financing. The financing comprised a $115 million Series A; based on the rapid progress of the science and the company, Prime Medicine expanded its syndicate support with a $200M Series B financing approximately nine months after the company began operations. Investors in the Series A included ARCH Venture Partners, F-Prime Capital, GV, and Newpath Partners.
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
Generate BiomedicinesGenerate BiomedicinesNot available$ xx.xxSeries C$1.95B$11.85$288MM
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM
OriginOriginNot available$ xx.xxNot available------

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
SpaceX SpaceX $587.07 +$6.05 (1.04%)High $xxx.xx
Anduril Anduril $107.59 +$2.77 (2.64%)High $xxx.xx
Databricks Databricks $197.65 -$0.01 (0.01%)High $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
Anduril Anduril $107.59 +$2.77 (2.64%)High $xxx.xx
Databricks Databricks $197.65 -$0.01 (0.01%)High $xxx.xx
Perplexity Perplexity $69.54 +$6.59 (10.47%)High $xxx.xx

Forge, your trusted partner for pre-IPO insights and Prime Medicine data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Dec 11, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.